Document is current
Any future updates will be listed below
-
Authors
Hao, Liangliang https://orcid.org/0000-0001-7513-3922
Zhao, Renee T. https://orcid.org/0000-0002-5627-4241
Welch, Nicole L.
Tan, Edward Kah Wei https://orcid.org/0000-0001-7933-1723
Zhong, Qian
Harzallah, Nour Saida https://orcid.org/0009-0008-3420-8391
Ngambenjawong, Chayanon https://orcid.org/0000-0002-2342-7977
Ko, Henry https://orcid.org/0000-0003-3665-5407
Fleming, Heather E. https://orcid.org/0000-0002-5286-3794
Sabeti, Pardis C.
Bhatia, Sangeeta N. https://orcid.org/0000-0002-1293-2097
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (K99CA237861, P30-CA14051, P30-CA14051, P30-CA14051, P30-CA14051, P30-CA14051, P30-CA14051, P30-CA14051, P30-CA14051)
U.S. Department of Health & Human Services | NIH | National Institute of Environmental Health Sciences (P30-ES002109, P30-ES002109, P30-ES002109, P30-ES002109, P30-ES002109, P30-ES002109, P30-ES002109, P30-ES002109)
Howard Hughes Medical Institute
- License Information
-
More Information
Article History
Received: 18 June 2021
Accepted: 10 March 2023
First Online: 24 April 2023
Competing interests
: S.N.B., L.H., R.T.Z. and C.N. are listed as inventors on patent applications related to the content of this work. S.N.B. holds equity in Glympse Bio, Satellite Bio, Lisata Therapeutics, Port Therapeutics, Intergalactic Therapeutics, Matrisome Bio, and is a director at Vertex; consults for Moderna, and receives sponsored research funding from Johnson & Johnson, Revitope, and Owlstone. The remaining authors declare no competing interests.
